Sansoè Giovanni, Ferrari Alberto, Baraldi Enrica, Castellana Carmen Nives, Biava Alessandra, Silvano Stefano, Rosina Floriano, Bonardi Lorenzo, Manenti Federico
Gastroenterology Unit, Gradenigo Hospital, Turin, Italy.
Dig Dis Sci. 2002 Feb;47(2):392-400. doi: 10.1023/a:1013738626256.
In normal humans, plasma dopamine levels rise during head-out water immersion or saline intravenous infusion. Dopamine inhibits Na+,K+-ATPase activity in the proximal tubule and blunts aldosterone secretion leading to increased diuresis and natriuresis. The aim of this study is to evaluate the role of endogenous dopaminergic activity in the intrarenal sodium handling in patients with compensated liver cirrhosis. We studied nine healthy controls and 12 patients with Child-Pugh A cirrhosis during a normosodic diet for (1) dopaminergic activity, as measured by the incremental aldosterone responses 30 and 60 min after intravenous metoclopramide administration; (2) basal plasma levels of active renin and aldosterone; (3) 4-hr renal clearance of lithium (an index of fluid delivery to the distal tubule), creatinine, sodium, and potassium, first without and then with dopaminergic blockade with intravenous metoclopramide. The patients displayed greater endogenous dopaminergic activity, evidenced by higher incremental aldosterone responses compared with controls (+30 min: 160.2 +/- 68.8 vs 83.6 +/- 35.2 pg/ml, P < 0.01; +60 min: 140.5 +/- 80.3 vs 36.8 +/- 39.1 pg/ml, P < 0.01, respectively). In spite of this, patients and controls did not show significantly different basal aldosterone plasma levels, delivery of sodium to the distal nephron, or urinary excretion of sodium. In both groups the dopaminergic blockade with metoclopramide determined no change in sodium and potassium urinary excretion, but it caused a fall of the fluid and sodium delivery from the proximal tubule to the distal nephron among the patients (from 30.7 +/- 9.3 to 14.4 +/- 4.5 ml/min, P < 0.001; and from 4.25 +/- 1.30 to 2.00 +/- 0.64 meq/min, P < 0.001, respectively). In this group the natriuresis was maintained due to a reduction of the reabsorbed fraction of the distal sodium delivery (from 97.5 +/- 1.9% to 89.8 +/- 12.4%, P < 0.05). In conclusions, compensated cirrhotic patients display an increased endogenous dopaminergic activity compared with controls. This function is critical in maintaining the delivery of sodium to the distal nephron.
在正常人体中,头露出水面的水浸试验或静脉输注生理盐水时,血浆多巴胺水平会升高。多巴胺可抑制近端肾小管中的Na + ,K + -ATP酶活性,并抑制醛固酮分泌,从而导致利尿和利钠增加。本研究的目的是评估内源性多巴胺能活性在代偿期肝硬化患者肾内钠处理中的作用。我们研究了9名健康对照者和12名Child-Pugh A级肝硬化患者,这些患者在正常钠饮食期间进行了以下检测:(1) 通过静脉注射甲氧氯普胺后30分钟和60分钟时醛固酮的增量反应来测量多巴胺能活性;(2) 活性肾素和醛固酮的基础血浆水平;(3) 锂(远端肾小管液体输送指标)、肌酐、钠和钾的4小时肾清除率,首先在未使用多巴胺能阻滞剂时进行测量,然后在静脉注射甲氧氯普胺进行多巴胺能阻滞时进行测量。与对照组相比,患者表现出更高的内源性多巴胺能活性,醛固酮增量反应更高(+30分钟:160.2±68.8 vs 83.6±35.2 pg/ml,P<0.01;+60分钟:140.5±80.3 vs 36.8±39.1 pg/ml,P<0.01)。尽管如此,患者和对照组的基础醛固酮血浆水平、远端肾单位的钠输送或尿钠排泄并没有显著差异。在两组中,甲氧氯普胺引起的多巴胺能阻滞并未导致钠和钾的尿排泄发生变化,但在患者中,它导致了从近端肾小管到远端肾单位的液体和钠输送减少(分别从30.7±9.3降至14.4±4.5 ml/min,P<0.001;从4.25±1.30降至2.00±0.64 meq/min,P<0.001)。在该组中,由于远端钠输送的重吸收分数降低(从97.5±1.9%降至89.8±12.4%,P<0.05),利钠作用得以维持。总之,与对照组相比,代偿期肝硬化患者的内源性多巴胺能活性增加。该功能对于维持钠向远端肾单位的输送至关重要。